news
New monoclonal antibody drug could combat antimicrobial resistance
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
List view / Grid view
Targets
article
Initial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
article
Drug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
news
BCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
article
Overcoming operational challenges in CGT manufacturing with AI
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing…
news
Damaged small intestine repaired with hPSC-derived organoids
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
news
New network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
webinar
Overcoming critical challenges in AI-driven drug discovery
16 September 2024 | By Drug Target Review
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer…
news
Sino Biological and BioGeometry: advancing protein R&D
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.
news
NSD2’s role in driving prostate cancer development
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
news
Giving rise to more complex organoids with microbeads
Microbeads enabled the precise release of signal molecules at any time or location within retinal organoids.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
news
Most comprehensive human endometrium map created
The publicly available Human Endometrial Cell Atlas could progress the development of therapeutics for endometriosis.
article
Rapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
news
Identifying disease-promoting microenvironments in AKI
The study’s findings could contribute to future therapeutic strategies to prevent chronic kidney disease.